On Tuesday, Citi updated its financial model for Belgian biopharmaceutical company UCB SA (UCB:BB) (OTC: UCBJY) shares, increasing the price target from EUR161.00 to EUR178.00. The firm maintained its Buy rating on the stock.
The revised target reflects enhanced sales projections for UCB's drugs Bimzelx and Rystiggo, which are now expected to achieve peak sales of €5.0 billion and €1.2 billion, respectively. The potential for patent term extensions for these drugs has also been factored into the new price target.
Citi's analysis suggests that sales dynamics for Cimzia, another of UCB's products, could be positively impacted by further anticipated delays in introducing biosimilar competitors. Additionally, UCB is expected to regain the rights for Cimzia in Japan by 2026, which could further boost the drug's performance.
The analyst also pointed out the notable contribution of Evenity, a treatment for osteoporosis, which is projected to account for 15-30% of UCB's EBITDA between 2024 and 2030.
UCB's financial exposure to royalties from the recently approved drug Niktimvo for the treatment of graft-versus-host disease (GvHD) was also highlighted. The royalties are estimated to be worth €7 per share. Citi's model has adjusted the firm's operational expenses upwards.
The report emphasizes UCB's diverse pipeline of potential treatments. It assumes that upcoming data readouts for lupus, Alzheimer's, and Parkinson's disease could present upside risks, as they are currently modeled with the expectation of negative outcomes.
The analyst noted that successfully advancing one of UCB's atopic dermatitis assets into Phase III trials could validate the company's forecasts.
Citi projects a compound annual growth rate (CAGR) for UCB's sales, EBITDA, and earnings per share (EPS) from 2024 to 2029 at 11%, 27%, and 32%, respectively. These figures place Citi's estimates 5-22% above the consensus for the period up to 2029 and over 30% beyond that.
InvestingPro Insights
As UCB SA (OTC: UCBJY) continues to capture the attention of investors and analysts alike, real-time data from InvestingPro enriches the narrative of the company's prospects. With a market capitalization of $32.46 billion and a high P/E ratio of 122.9, reflecting a market that has high expectations for the company's future earnings. However, the adjusted P/E ratio for the last twelve months as of Q2 2024 stands at a slightly lower 105.86, indicating a potential normalization of earnings expectations over time.
InvestingPro Tips highlight UCB's commitment to shareholder returns, with the company having raised its dividend for 15 consecutive years and maintaining dividend payments for 45 consecutive years. This is a testament to UCB's financial resilience and dedication to consistent shareholder value. Moreover, analysts predict the company to be profitable this year, which aligns with Citi's optimistic projections for the company's growth.
UCB's stock has experienced a strong return over the last year, with a year-to-date price total return of an impressive 97.13%, and it is currently trading near its 52-week high, at 98.41% of the high. These metrics underscore the stock's robust performance and the market's positive reception to UCB's strategic initiatives and product pipeline.
For readers interested in a deeper dive into UCB's financial health and future prospects, additional InvestingPro Tips can be found at https://www.investing.com/pro/UCBJY, providing a comprehensive toolset for informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.